Antihypertensive medications and erectile dysfunction: is this association accurate?
The Journal of Sexual Medicine · 29.06.2025 · 22 (7) · 1285-1286
DOI: 10.1093/jsxmed/qdaf108 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Sexual Medicine, online erschienen am 26.05.2025. Verfasst von Andrew Rosenzweig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Albany Medical Center, Albany, NY 12208, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Studies examining erectile dysfunction (ED) rates among antihypertensive medications (AM) have produced conflicting results, generating uncertainty about the true clinical impact of AM on erectile function.1 While the American Urologic Association ED guidelines do not comment on this association, the American Heart Association (AHA) guidelines do consider that AMs may contribute to ED. Using post-marketing reported data, we attempted to remove biases looking at the association between AMs and ED that may be generated by previous studies. We utilized the Food and Drug Administration’s adverse event reporting database (FAERS) to evaluate ED rates by different medication and class. Using this database, we collated adverse events for AMs in the AHA guidelines from 2013 to 2020. Data were also compiled for each medication class. The medications that were analyzed were angiotensin-converting enzyme inhibitors (ACE-I) including benazepril, enalapril, lisinopril, quinapril, and ramipril; angiotensin receptor blockers (ARBs) including irbesartan, losartan, olmesartan, and valsartan; calcium channel blockers including verapamil, diltiazem, nifedipine, and amlodipine; beta blockers including carvedilol, propranolol, metoprolol, atenolol, labetalol, bisoprolol, and nebivolol; thiazide diuretics including chlorthalidone and hydrochlorothiazide; loop diuretics including bumetanide, furosemide, and torsemide; mineralocorticoid receptor antagonists including spironolactone; centrally acting agents including clonidine and guanfacine; vasodilators including hydralazine, isosorbide mononitrate, and isosorbide dinitrate; and alpha one blockers including doxazosin, prazosin, and terazosin.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Albany Medical Center, Albany, NY 12208, United States.
Zitieren
APA
Rosenzweig, A., Visingardi, J., Feustel, P., Pignanelli, M., De, E., Inouye, B., & Welliver, C. (2025). Antihypertensive medications and erectile dysfunction: is this association accurate?. The Journal of Sexual Medicine, 22(7), 1285-1286. https://doi.org/10.1093/jsxmed/qdaf108
Vancouver
Rosenzweig A, Visingardi J, Feustel P, Pignanelli M, De E, Inouye B, et al. Antihypertensive medications and erectile dysfunction: is this association accurate?. The Journal of Sexual Medicine. 2025;22(7):1285-1286. doi:10.1093/jsxmed/qdaf108
BibTeX
@article{Rosenzweig2025,
author = {Rosenzweig, Andrew and Visingardi, Joseph and Feustel, Paul and Pignanelli, Michael and De, Elise and Inouye, Brian and Welliver, Charles},
title = {Antihypertensive medications and erectile dysfunction: is this association accurate?},
journal = {The Journal of Sexual Medicine},
year = {2025},
volume = {22},
number = {7},
pages = {1285--1286},
doi = {10.1093/jsxmed/qdaf108}
}
EUVIMED